Ownership and insider activity for Nanobiotix S.A. (NBTX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles.
Price
| Price | $34.40 |
| Market Cap | $1.7B |
| Exchange | NASDAQ |
| Country | FR |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $21.1M | $47.2M | $36.2M | $35.1M | $119.2M | $83.9M | $41.4M | $75.3M | $49.7M | $52.8M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $5207 | $844000 | $997000 | $1.3M | $3.9M | $3.9M | $2.8M | $3.0M | $8.5M | $7.7M |
| Inventory | -$5.0M | -$4.9M | $1.1M | $2.7M | 0 | 0 | $3.0M | $200000 | 0 | 0 |
| Total Current Assets | $26.9M | $53.1M | $42.7M | $46.1M | $125.2M | $93.1M | $52.4M | $87.3M | $61.5M | $62.8M |
| Property, Plant & Equipment | $2.4M | $3.0M | $2.9M | $9.4M | $8.3M | $8.2M | $7.1M | $6.1M | $5.5M | $4.6M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $4453 | $135968 | $102000 | $163000 | $21000 | $4000 | $1000 | $8000 | $7000 | $10000 |
| Total Assets | $30.4M | $57.5M | $46.2M | $56.2M | $134.0M | $101.8M | $59.8M | $93.9M | $67.4M | $67.8M |
| Accounts Payable | $4.4M | $5.1M | $4.5M | $6.2M | $5.6M | $5.0M | $4.0M | $6.7M | $4.5M | $6.6M |
| Short-term Debt | $1.1M | $770000 | $500000 | $500000 | $3.7M | $7.1M | $3.6M | $3.8M | $3.7M | $3.1M |
| Total Current Liabilities | $8.2M | $9.4M | $11.6M | $14.3M | $19.0M | $36.8M | $37.9M | $49.9M | $58.9M | $57.5M |
| Long-term Debt | $4.6M | $3.7M | $20.0M | $37.6M | $39.1M | $32.4M | $44.0M | $41.7M | $43.0M | $89.1M |
| Total Liabilities | $13.0M | $13.5M | $32.0M | $58.1M | $63.6M | $75.0M | $86.8M | $95.7M | $133.1M | $152.2M |
| Retained Earnings | -$21.9M | -$26.1M | -$30.3M | -$50.9M | -$33.6M | -$47.0M | -$57.0M | -$39.7M | -$68.1M | -$24.0M |
| Total Equity | $17.4M | $43.9M | $14.2M | -$1.9M | $70.5M | $26.8M | -$27.0M | -$1.8M | -$65.7M | -$84.5M |
| Total Debt | $5.7M | $4.7M | $20.5M | $44.5M | $49.0M | $46.0M | $53.2M | $50.6M | $50.9M | $95.3M |
| Net Debt | -$15.4M | -$42.5M | -$15.7M | $9.4M | -$70.2M | -$38.1M | $11.8M | -$24.7M | $1.2M | $42.6M |
| Working Capital | $18.6M | $43.8M | $31.1M | $31.8M | $106.2M | $56.2M | $14.4M | $37.5M | $2.5M | $5.2M |
Financial Health
| Debt / Equity | -1.13 |
| Current Ratio | 1.09 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 3.22 |
Profitability
| Return on Equity | 31.23% |
| Return on Invested Capital | -74.29% |
| Return on Assets | -35.36% |
| Gross Margin | 100.00% |
| Operating Margin | -36.49% |
| Net Margin | -80.83% |
Related companies: ABUS · EYPT · GHRS · KURA · LENZ · PROK · RZLT
Explore sector: Healthcare · Biotechnology
More sections of NBTX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks